PIK3CA and breast cancer: Alpelisib is another α-selective PIK3CA inhibitor that demonstrated a significant improvement in progression-free survival when added to fulvestrant for HR+/HER2- PIK3CA-mutant advanced BC in the SOLAR-1 trial [84].